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Abstract
Resveratrol (Resv) is natural polyphenol found in grapes. This study evaluated the protective effect of Resv against the effects
of uric acid (UA) in immortalized human mesangial cells (ihMCs). ihMCs were preincubated with Resv (12.5 mM) for 1 h and
treated with UA (10 mg/dL) for 6 or 12 h. The intracellular calcium concentration [Ca2+]i was quantified by fluorescence using
flow cytometry. Angiotensinogen (AGT) and pre-pro endothelin-1 (ppET-1) mRNA were assayed by quantitative real-time RT-
PCR. Angiotensin II (AII) and endothelin-1 (ET-1) were assayed by ELISA. UA significantly increased [Ca2+]i. Pre-incubation
with Resv significantly reduced the change in [Ca2+]i induced by UA. Incubation with UA for 6 or 12 h also increased AGT
mRNA expression and AII protein synthesis. Resv blunted these increases in AGT mRNA expression and AII protein.
Incubation with UA in the ihMCs increased ppET-1 expression and ET-1 protein synthesis at 6 and 12 h. When ihMCs were
pre-incubated with Resv, UA had a significantly diminished effect on ppET-1 mRNA expression and ET-1 protein synthesis at 6
and 12 h, respectively. Our results suggested that UA triggers reactions including AII and ET-1 production in mesangial cells.
The renin-angiotensin system may contribute to the pathogenesis of renal function and chronic kidney disease. Resv can
minimize the impact of UA on AII, ET-1 and the increase of [Ca2+]i in mesangial cells, suggesting that, at least in part, Resv
can prevent the effects of soluble UA in mesangial cells.
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Introduction
Resveratrol (Resv), a phenolic compound with signifi-
cant biological activity, is of great interest to several
research groups worldwide (1,2). Dietary intake of Resv in
grapes, red wine, peanuts, purple grape juice, and berries
may have beneficial effects on human heath (1-7), and
may have health-promoting antinephrolithic, antidiabetes,
anticancer, antioxidation, anti-inflammation, cardioprotec-
tive, chemopreventive, and neuroprotective properties
(5-9). In addition, Resv may prevent renal lipotoxicity
and have antihyperuricemic activity (10,11).
Several pathways are thought to be related to the
protective effect of Resv. In a nephrolithic model, about
70% of kidney stones were composed of calcium oxalate
(CaOx), which causes renal cell injury through the
production of reactive oxygen species (ROS) and
nicotinamide adenine dinucleotide phosphate (NADPH)
when deposited in kidney tissue (12). Resv exerts its
antinephrolithic potential via the inhibition of ROS,
monocyte chemoattractant protein-1 (MCP-1), hyaluro-
nan, and osteopontin (OPN) signaling (13). Resv has
been shown to suppress the migration of oxalate-treated
human renal epithelial cells (HRCs), It also can attenuate
the expression of NADPH oxidase subunit, MCP-1, and
OPN mRNAs, and downregulate the expression of
transforming growth factor-b (TGF-b1), TGF-b receptor
and hyaluronan proteins in oxalate-treated HRCs (13).
Diabetic nephropathy is a serious complication of type
1 and type 2 diabetes. It is characterized by an expansion
of the glomerular mesangium caused by mesangial cell
proliferation and an excess of extracellular matrix (ECM)
proteins synthesized by mesangial cells (14). There is
increasing evidence that overproduction of ROS is
involved in the development of diabetic nephropathy
(15,16) by activating protein kinase C, mitogen-activated
protein (MAP) kinases, and transcription factors nuclear
factor kappa beta (NF-kB) and activated protein-1. The
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resulting altered expression of genes and ECM proteins
leads to diabetic nephropathy (17). Mesangial cell
proliferation and fibronectin expression are induced by
hyperglycemia through the janus kinase (JNK)/NF-kB/
NADPH oxidase/ROS signaling pathway (14). Resv has
been shown to inhibit hyperglycemia-induced mesangial
cell expansion and fibronectin expression by blocking this
signaling pathway (14).
Hyperuricemia, present as a metabolic disorder, is
usually associated with gout, kidney disease, hyperten-
sion, cardiovascular diseases, inflammation, diabetes and
metabolic syndrome. There is increasing evidence that
hyperuricemia is an independent risk factor for the
occurrence and development of kidney disease, including
damage to mesangial cells. At least one study reported
that Resv has antihyperuricemic and nephroprotective
activity in oxonate-induced mice (18). These effects,
mediated by changes in renal expression of mGLUT9,
mABCG2, mOAT1, and mOCT1, are evidence of the
possible preventive efficacy of Resv on hyperuricemia
(11,18). The present study analyzed the effects of Resv
on uric acid (UA)-treated mesangial cells as well as
effects on the renin-angiotensin system (RAS) and the
endothelin system.
Material and Methods
Cell culture
Immortalized human mesangial cells (ihMCs), kindly
provided by Dr. Richard Banas (Munich, Germany), were
grown in Dulbecco’s modified eagle medium (DMEM;
Gibco, USA) with the addition of 10% fetal bovine serum
(FBS; Gibco), 24 mM NaHCO3 (Merck, USA), 10 mM
HEPES (Sigma, USA) and 10,000 U/L penicillin/strepto-
mycin (Gibco). The cultures were incubated at 376C in a
humidified atmosphere containing 5% carbon dioxide.
When semiconfluent, the cells were detached from the
plastic flasks with trypsin (0.5%; Cultilab, Brazil), centri-
fuged for 5 min at 1000 g, and then resuspended in
DMEM and subcultured in 22-cm2 plastic culture flasks for
further experimental procedures.
Resv preparation
Resv of 99% purity (Sigma) was dissolved in DMSO
(Merck), and stored at –206C in the dark.
Uric acid preparation
UA (Sigma) was sterilized in a steam autoclave and
added to culture medium without FBS. The UA crystals
were suspended in DMEM containing 1% FBS, incubated
at 376C, and sonicated for 15 min to solubilize the crystals.
Exposure of the ihMCs to uric acid
Prior to the experiments, ihMCs were transferred to a
plastic plate (16106 cells/plate) and maintained under
culture conditions for 3 days. At confluence, the cells were
exposed for 6 or 12 h to either DMEM, without FBS, for
the control or DMEM containing 10 mg/dL UA.
RNA isolation, reverse transcription and quantitative
real-time PCR
Total RNA was isolated and purified from ihMCs by a
phenol and guanidine isothiocyanate-cesium chloride
method, using the appropriate kit (Trizol; Life
Technologies, USA). Two micrograms of total RNA were
treated with DNase (RQ1 RNase-Free DNase; Promega,
USA) to prevent genomic DNA contamination. The RNA
pellet was resuspended in RNase-free water and was
reverse transcribed into cDNA by the addition of 0.5 mg/
mL oligo d(T), 10 mM dithiothreitol (DTT), 0.5 mM dNTPs
(GE Healthcare, UK), and 200 U reverse transcriptase
enzyme (SuperScript RT, Gibco, USA).
Real-time amplification was carried out with a 7500Real-
Time Sequence Detection System (SDS; ABI Prism 7500;
Applied Biosystems, USA). The real-time PCR product
was quantified using an intercalating dye (SYBR Green I;
Molecular Probes Inc., USA) that exhibits increased
fluorescence upon binding double-stranded DNA.
The relative gene expression was calculated using the
conditions at the early stages of the PCR. At this point, the
amplification is logarithmic and can thus be correlated to
the initial copy number of the gene transcripts. The reactions
were cycled 40 times under the conditions previously
determined by conventional PCR. The fluorescence for
each cycle was quantitatively analyzed using an ABI Prism
7500 SDS (Applied Biosystems). At the end of the PCR
reaction, the temperature was increased from 606C to 956C
at a rate of 26C/min. During that time, fluorescence was
measured every 15 s to construct a melting curve. A
nontemplate control was run with each assay.
The PCR was performed with primers specific for
pre-pro endothelin-1 (ppET-1), angiotensinogen (AGT),
and b-actin. The primer sequences were: ppET-1 sense
(59-GAGAAACCCACTCCCAGTCC-39) and antisense
(59-GATGTCCAGGTGGCAGAAGT-39); b-actin, sense
(59-TCACCCACACTGTGCCCATCTACGA-39) and anti-
sense (59-CAGCGGAACCGCTCATTGCCAATGG-39);
and AGT sense (59-ACTTCTCGGTGACTCAAGTGCC-39)
and antisense (59-GAAAGTGAGACCCTCCACCTTGT-39).
The results of these experiments are reported in each group
as the relative expression normalized to the b-actin house-
keeping gene. This genewas used as an internal control and
is expressed here as a percentage of the control reaction.
Real-time data analysis
The cycle threshold (Ct) values were subtracted from
the Ct value for each gene to yield the DCt values. These
values were used for statistical comparisons. For the
graphic representations, the fold variation was determined
using the 2–(DDCt) method according to published proto-
cols (19) and manufacturer recommendations. The fold
variations were calculated by determining the difference in
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the DCt values between the chosen reference and the test
samples (DDCt value), with subsequent application of the
2–(DDCt) formula.
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of angiotensin II (AII) and endothelin
(ET)-1 were assayed in cell cultures treated with UA using
a commercially available competitive ELISA (Cayman
Chemical, USA). All assays were performed according
to the manufacturer’s protocols. The absorbance of each
sample was determined using an Ultra Microplate (Biotek,
USA) and reported as ng/mL and pg/mL.
Measurement of intracellular calcium by flow
cytometry
For the cytometric analyses, the cells were cultured to
a density of 26106 cells/well, were pretreated with Resv
(12.5 uM) and stimulated with UA (10 mg/dL). The cells
were then trypsinized, washed twice with PBS, and
resuspended in 0.5 mL isotonic solution. The osmolarity
of the isotonic solution was 323±6 mOsm and consisted
of 80 nM D-mannitol with 120 mM NaCl, 6 mM KCl, 1 mM
MgCl2, 2 mM CaCl2, and 5.4 mM HEPES. The cells were
loaded with 2 mM fluo-4/AM (Invitrogen, USA) for 30 min
and were analyzed by flow cytometry (BD FACSCanto II,
BD Biosciences, USA) at an excitation wavelength of
488 nm and an emission wavelength of 525 nm. The
fluorescence intensity of approximately 16106 labeled
cells was measured in each assay, and the data are
reported as the median fluorescence intensity in arbitrary
units (AU) obtained by averaging at least 3 separate
experiments (20).
Statistical analysis
The data are reported as means±SE. The experi-
mental and control groups were compared via the Student
t-test. The significance level for the null hypothesis was
set at 5% (P,0.05).
Results
Resv inhibited the increase in [Ca2+]i induced by UA
To study the effect of Resv on mesangial cells, the
effect of UA was first analyzed. Treatment of ihMCs with
10 mg/dL UA increased [Ca2+]i (80.60±0.20) compared
with the fluorescence at baseline, but the increase in AII
was greater than that of [Ca2+]i after UA administration.
The effect of UA was inhibited by pre-exposure of
mesangial cells to Resv. When the ihMCs were pre-
incubated with 12.5 mM Resv for 1 h, [Ca2+]i, as
estimated by fluorescence intensity, was 38.34±0.01
compared to 80.60±0.20 in cells that had not been
pretreated (P,0.005; Figure 1).
Resv inhibited the RAS system in the mesangial cells
One of the main regulators of contraction in mesangial
cells is the peptide AII; therefore, we evaluated the effect
of Resv on UA-induced AII synthesis. There was a
significant increase in UA-induced AGT mRNA expres-
sion in the ihMCs in a time-dependent manner. Incubation
of the ihMCs with 10 mg/dL UA significantly increased
AGT mRNA expression at 6 h (12.40±0.92 vs
1.24±0.18 AU for the control, P,0.001) and at 12 h
(22.04±0.79 vs 1.24±0.18 AU for the control, P,0.001).
When ihMCs were pre-incubated with 12.5 mM Resv for
1 h, the increase in AGT mRNA was not as great at 6 h
(12.40±0.92 vs 3.03±1.08 AU for the UA condition) and
at 12 h (22.04±0.79 vs 5.36±1.06 AU for the UA
condition) (both P ,0.001, Figure 2A).
UA increased AII protein synthesis at 6 h (0.07±0.01
vs 0.05±0.01 ng/mL for the control, P,0.05) and 12 h
(0.10±0.01 vs 0.05±0.01 ng/mL for the control, P,0.05)
Pre-incubation with 12.5 mM Resv for 1 h attenuated the
increase in AII protein synthesis at 6 h (0.05±0.01 vs
0.07±0.01 ng/mL for the UA group) and at 12 h
(0.04±0.003 vs 0.10±0.01 ng/mL for the UA group)
(both P,0.05, Figure 2B).
Resv inhibited the endothelin system in mesangial
cells
ET-1 is also a peptide involved in smooth muscle cell
contraction (21). Nevertheless, the effect of UA on ET-1
synthesis in mesangial cells is not known. UA significantly
increased ppET-1 mRNA expression in cultured ihMCs in a
time-dependent manner. Incubation of the ihMCs with UA
increased ppET-1 expression at 6 h (1.52±0.23 vs
1.02±0.10 AU for the control group) and 12 h
(2.32±0.18 vs 1.02±0.10 AU for the control group) (both
P,0.05, Figure 3A). When the ihMCs were pre-incubated
with 12.5 mM Resv for 1 h, the increases were significantly
Figure 1. Intracellular calcium concentration in immortalized
human mesangial cells (ihMCs) treated with uric acid (UA) and
resveratrol (Resv). Briefly, semi-confluent ihMC cells were
detached with trypsin and the fluorescence intensity of intracel-
lular calcium was determined by Fluo-4/AM in the presence of
10 mg/dL UA and 12.5 mM Resv. Data are reported as the mean
percentage (±SE). *P,0.001 vs control (CTL); **P,0.005 vs UA
(Student t-test).
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lower at both 6 h (0.77±0.18 vs 1.52±0.23 arbitrary units
for the UA group) and 12 h (0.41±0.06 vs 2.32±0.18
arbitrary units for the UA group (both P,0.05, Figure 3A).
UA increased ET-1 protein synthesis at 6 h
(32.69±0.22 vs 29.68±0.35 pg/mL for the control group)
and 12 h (37.29±1.23 vs 29.68±0.35 pg/mL for the
control group (both P,0.05, Figure 3B).
Again, when the ihMCs were pre-incubated with
12.5 mM Resv for 1 h, the increases were significantly
lower in ET-1 protein synthesis at 6 h (27.78±1.38 vs
32.69±0.22 pg/mL for the UA group) and at 12 h
(29.92±1.02 vs 37.29±1.23 pg/mL for the UA group
(all P,0.05, Figure 3B).
Discussion
Mesangial cells play a major role in glomerular
contraction and regulate filtration surface area and
ultrafiltration coefficient (Kf) through the release of
hormones such as AII. Mesangial cells express all
components of RAS, and can regulate the Kf via
contraction or the release of vasoactive hormones (22).
ETs are also powerful vasoconstrictor peptides, and act
as modulators of vasomotor tone, cell proliferation, and
hormone production. Mesangial cells are the main site of
ET production in the kidney (23).
UA has recently been recognized as a key factor in
multifactorial renal disorders, including chronic kidney
disease, hypertension and acute kidney injury (24,25).
Recent studies have confirmed that RAS is strongly related
to elevated serum UA levels in hypertensive patients. We
have previously demonstrated that UA stimulates RAS and
ET-1 in mesangial cells after 24 h (26). Experimental
studies in vitro have also demonstrated that UA has direct
effects on rat vascular smooth cell, proliferation (27),
human vascular endothelial cell dysfunction (28), and ihMC
proliferation (26) via local tissue RAS activation. This
evidence indicates that the activation of systemic and local
tissue RAS by UA may be partially responsible for the
pathogenetic effects of UA in hypertension.
The experimental choice of 10 mg/d UA was deter-
mined by the saturation concentration of monosodium
urate in human plasma of approximately 7 mg/dL. Thus,
the definition of hyperuricemia is usually a plasma UA
concentration .7 mg/dL (29). In addition, Aida et al. (30)
Figure 2. Effect of resveratrol (Resv) treatment on the
angiotensinogen mRNA expression (A) and AII protein synthesis
(B) in immortalized human mesangial cells (ihMCs) stimulated
with uric acid (UA). Cells were seeded onto plates and after 6 and
12 h were exposed to DMEM with 1% FBS containing 10 mg/dL
UA, and 12.5 mM Resv. Data are reported as means±SE.
*P,0.001 vs control (CTL); **P,0.001 vs UA (Student t-test).
Figure 3. Effect of resveratrol (Resv) treatment (12.5 mM) on
mRNA pre-pro endothelin-1 (ppET-1) expression (A) and ET-1
protein synthesis (B) in immortalized human mesangial cells
(ihMCs) stimulated with uric acid (UA). Cells were seeded on
plates and after 6 and 12 h were exposed to DMEM with 1% FBS
containing 10 mg/dL UA and 12.5 mM Resv. Data are reported as
means±SE. A, *P,0.05 vs control (CTL); **P,0.05 vs UA
(Student t-test). B, *P,0.05 vs CTL; **P,0.001 vs UA (Student
t-test).
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reported that the plasma concentration of UA in the
general population has a wide range, extending from 1 to
12 mg/dL. Observations in an American cohort were
confirmed in a community-based study with participants in
Vienna that reported mild hyperuricemia in patients with
uric acid concentrations of 7.0-8.9 mg/dL (31). High UA
concentrations (5 or 15 mg/dL) upregulated both RAS
mRNA expression and AII II protein secretion in 3T3-L1
adipocytes. In addition, UA caused a significant increase
in ROS production in differentiated adipocytes (32).
Evidence from studies indicates that the generation of
ROS is, at least in part, involved in endothelial dysfunction
(33,34), and the production of ROS, particularly the
superoxide anion (O2
-), is closely related to calcium
concentration (35).
The concentration of Resv (12.5 mM) was chosen from
among various concentrations that are known to have
relevant cardiovascular effects on isolated tissues or
organs (36). The first evidence of the specific benefits of
red wine was shown in 1993 when Frankel et al. (37)
demonstrated that red wine diluted 1000-fold and contain-
ing 10 mmol of total phenols inhibited the oxidation of LDL.
This is approximately the Resv concentration found in red
wines, and suggested that half a bottle of such wine
should contain an active concentration of resveratrol (37).
In a study similar to ours, Chao et al. (38) found that Resv
(10 mM) inhibited the formation of AII-induced ROS, extra-
cellular signal-regulated kinase phosphorylation, ET-1 gene
expression, and cell proliferation in smooth muscle cells.
In this study, UA induced an increase in ppET-1
mRNA expression and protein synthesis after 6 and 12 h
and increased AGT mRNA expression and AII protein
synthesis after 6 and 12 h. In addition, Resv reduced UA-
induced pre-proET-1 gene expression and the production
of AII and ET-1 in mesangial cells, suggesting that it can
minimize the impact of these hormones on glomerular
function. In addition, Resv inhibited the increase in
[Ca2+]i. These results are the first direct evidence that
UA induces an increase in [Ca2+]i that is minimized by
Resv. Our results suggested that UA triggers reactions
including AII and ET-1 production in mesangial cells. RAS
may contribute to the pathogenesis of renal function and
chronic kidney disease. Resv can minimize the impact of
UA on the increases of AII, ET-1 and [Ca2+]i in mesangial
cells, suggesting that it can prevent the effects of soluble
UA on mesangial cells.
Lastly, multidisciplinary approaches are recom-
mended for future investigations because of the wide
range of polyphenol actions on body fat reduction,
mitigation of liver disease, improvements in muscle
function, and cardiovascular and renal protection.
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